| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premature Birth | 13 | 2023 | 417 | 3.210 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2023 | 342 | 2.690 |
Why?
|
| Prenatal Care | 11 | 2023 | 360 | 1.840 |
Why?
|
| Glucocorticoids | 8 | 2024 | 395 | 1.680 |
Why?
|
| Pregnancy | 52 | 2024 | 7588 | 1.540 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 2022 | 82 | 1.440 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2013 | 62 | 1.140 |
Why?
|
| Pregnancy Complications | 7 | 2011 | 551 | 1.130 |
Why?
|
| Gestational Age | 12 | 2024 | 1227 | 1.120 |
Why?
|
| Pre-Eclampsia | 4 | 2020 | 230 | 1.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2024 | 243 | 1.020 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 673 | 1.000 |
Why?
|
| Amniotic Fluid | 5 | 2016 | 154 | 0.950 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2013 | 1007 | 0.910 |
Why?
|
| Obstetric Labor, Premature | 6 | 2011 | 84 | 0.900 |
Why?
|
| Fetal Viability | 1 | 2024 | 30 | 0.870 |
Why?
|
| Perinatal Care | 1 | 2024 | 68 | 0.840 |
Why?
|
| Antithrombin III | 2 | 2013 | 28 | 0.770 |
Why?
|
| Thrombin | 2 | 2013 | 62 | 0.760 |
Why?
|
| Peptide Hydrolases | 2 | 2013 | 149 | 0.720 |
Why?
|
| Progesterone | 3 | 2009 | 635 | 0.680 |
Why?
|
| Female | 54 | 2025 | 71342 | 0.600 |
Why?
|
| Edema | 3 | 2013 | 147 | 0.590 |
Why?
|
| Decision Making | 2 | 2024 | 698 | 0.590 |
Why?
|
| Dexamethasone | 6 | 2013 | 280 | 0.580 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 551 | 0.580 |
Why?
|
| Progestins | 2 | 2009 | 51 | 0.580 |
Why?
|
| Infant, Newborn | 11 | 2024 | 8531 | 0.530 |
Why?
|
| Fetal Organ Maturity | 4 | 2011 | 14 | 0.510 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 3 | 2004 | 6 | 0.500 |
Why?
|
| Humans | 62 | 2025 | 133017 | 0.490 |
Why?
|
| Diseases in Twins | 2 | 2005 | 99 | 0.460 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2016 | 169 | 0.450 |
Why?
|
| Breech Presentation | 2 | 2006 | 20 | 0.440 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 114 | 0.440 |
Why?
|
| Cultural Diversity | 1 | 2015 | 71 | 0.440 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 51 | 0.430 |
Why?
|
| Cultural Competency | 1 | 2015 | 53 | 0.430 |
Why?
|
| Cervix Uteri | 4 | 2013 | 64 | 0.420 |
Why?
|
| Breast Diseases | 2 | 2004 | 38 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1249 | 0.410 |
Why?
|
| Foot Diseases | 1 | 2013 | 23 | 0.400 |
Why?
|
| Turner Syndrome | 1 | 2013 | 45 | 0.390 |
Why?
|
| Delivery, Obstetric | 3 | 2018 | 260 | 0.380 |
Why?
|
| Cerclage, Cervical | 2 | 2009 | 12 | 0.380 |
Why?
|
| Pregnancy Outcome | 9 | 2008 | 636 | 0.380 |
Why?
|
| Pregnancy, High-Risk | 2 | 2009 | 43 | 0.370 |
Why?
|
| Betamethasone | 5 | 2011 | 14 | 0.360 |
Why?
|
| Cervical Ripening | 2 | 2008 | 7 | 0.350 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 448 | 0.340 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 905 | 0.340 |
Why?
|
| Uterine Cervical Incompetence | 2 | 2006 | 6 | 0.310 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 656 | 0.300 |
Why?
|
| Fetal Growth Retardation | 1 | 2011 | 257 | 0.300 |
Why?
|
| Proteinuria | 3 | 2020 | 110 | 0.300 |
Why?
|
| Placenta | 2 | 2016 | 548 | 0.290 |
Why?
|
| Labor Onset | 1 | 2008 | 4 | 0.290 |
Why?
|
| HELLP Syndrome | 1 | 2007 | 17 | 0.270 |
Why?
|
| Down Syndrome | 1 | 2010 | 232 | 0.260 |
Why?
|
| Adult | 18 | 2017 | 31725 | 0.250 |
Why?
|
| Heart Ventricles | 1 | 2011 | 757 | 0.250 |
Why?
|
| Vaginosis, Bacterial | 1 | 2006 | 19 | 0.250 |
Why?
|
| Trial of Labor | 1 | 2006 | 23 | 0.240 |
Why?
|
| Thanatophoric Dysplasia | 1 | 2005 | 6 | 0.240 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2005 | 20 | 0.240 |
Why?
|
| Oocyte Donation | 1 | 2025 | 7 | 0.240 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 47 | 0.240 |
Why?
|
| Airway Obstruction | 1 | 2007 | 167 | 0.230 |
Why?
|
| Time Factors | 7 | 2016 | 6482 | 0.230 |
Why?
|
| Estrogen Antagonists | 1 | 2005 | 107 | 0.220 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 105 | 0.220 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2025 | 76 | 0.220 |
Why?
|
| Transient Tachypnea of the Newborn | 1 | 2024 | 2 | 0.220 |
Why?
|
| Environmental Pollutants | 1 | 2005 | 79 | 0.220 |
Why?
|
| NF-kappa B | 1 | 2007 | 469 | 0.220 |
Why?
|
| Community Health Planning | 1 | 2003 | 8 | 0.210 |
Why?
|
| Maternal Exposure | 1 | 2005 | 156 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2020 | 77 | 0.200 |
Why?
|
| Mammaplasty | 1 | 2004 | 54 | 0.200 |
Why?
|
| Uterine Rupture | 1 | 2003 | 18 | 0.200 |
Why?
|
| Urogenital Abnormalities | 1 | 2005 | 168 | 0.200 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2003 | 98 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2024 | 192 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 401 | 0.190 |
Why?
|
| Hydrops Fetalis | 1 | 2002 | 85 | 0.190 |
Why?
|
| Cesarean Section | 2 | 2018 | 403 | 0.180 |
Why?
|
| Diabetes, Gestational | 1 | 2003 | 115 | 0.180 |
Why?
|
| Biomarkers | 4 | 2020 | 3405 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2025 | 506 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2003 | 182 | 0.180 |
Why?
|
| Cocaine | 1 | 2003 | 208 | 0.180 |
Why?
|
| Tocolytic Agents | 2 | 2011 | 12 | 0.180 |
Why?
|
| Risk Factors | 6 | 2016 | 10883 | 0.170 |
Why?
|
| Cocaine-Related Disorders | 1 | 2003 | 204 | 0.170 |
Why?
|
| Pregnancy, Multiple | 1 | 2000 | 48 | 0.160 |
Why?
|
| Embryo Transfer | 1 | 2000 | 61 | 0.160 |
Why?
|
| Maternal Age | 2 | 2011 | 141 | 0.160 |
Why?
|
| Eclampsia | 1 | 2020 | 29 | 0.160 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 968 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2016 | 471 | 0.160 |
Why?
|
| Cholecystectomy | 1 | 2019 | 63 | 0.150 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 1818 | 0.150 |
Why?
|
| Fetal Diseases | 1 | 2003 | 461 | 0.150 |
Why?
|
| Fertilization in Vitro | 1 | 2000 | 162 | 0.150 |
Why?
|
| Meningocele | 1 | 2018 | 18 | 0.140 |
Why?
|
| Mass Screening | 2 | 2020 | 832 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2003 | 680 | 0.140 |
Why?
|
| Lung | 5 | 2011 | 1563 | 0.130 |
Why?
|
| Parents | 1 | 2024 | 1075 | 0.130 |
Why?
|
| Hypertension | 1 | 2005 | 1348 | 0.130 |
Why?
|
| Creatinine | 2 | 2008 | 417 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 136 | 0.120 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 95 | 0.120 |
Why?
|
| Postpartum Hemorrhage | 1 | 2017 | 109 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2001 | 856 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 142 | 0.120 |
Why?
|
| Complement C4a | 1 | 2015 | 4 | 0.120 |
Why?
|
| Peptide Hormones | 1 | 2016 | 71 | 0.120 |
Why?
|
| Complement Factor B | 1 | 2015 | 11 | 0.120 |
Why?
|
| Complement C5a | 1 | 2015 | 22 | 0.120 |
Why?
|
| Peer Review | 1 | 2015 | 38 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 123 | 0.120 |
Why?
|
| Meningomyelocele | 1 | 2018 | 255 | 0.110 |
Why?
|
| Amniocentesis | 2 | 2012 | 77 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2009 | 998 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1158 | 0.110 |
Why?
|
| Brain | 2 | 2024 | 3216 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2016 | 178 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 746 | 0.110 |
Why?
|
| Publishing | 1 | 2015 | 116 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2007 | 4847 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2013 | 629 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Hypoxia, Brain | 1 | 2013 | 35 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 139 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1306 | 0.090 |
Why?
|
| Syndrome | 2 | 2007 | 1173 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2018 | 1260 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2011 | 19 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3123 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 748 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 123 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2015 | 3429 | 0.090 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2009 | 9 | 0.080 |
Why?
|
| Chimerism | 1 | 2010 | 29 | 0.080 |
Why?
|
| Parity | 1 | 2010 | 87 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2011 | 239 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 765 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 380 | 0.080 |
Why?
|
| Fetal Mortality | 1 | 2008 | 7 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 3085 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2011 | 207 | 0.070 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2008 | 33 | 0.070 |
Why?
|
| Procollagen | 1 | 2008 | 17 | 0.070 |
Why?
|
| Uremia | 1 | 2008 | 35 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2004 | 3781 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 42 | 0.070 |
Why?
|
| Glomerulonephritis | 1 | 2008 | 75 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2008 | 42 | 0.070 |
Why?
|
| Cleft Lip | 1 | 2010 | 133 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2008 | 124 | 0.070 |
Why?
|
| Cleft Palate | 1 | 2010 | 153 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 58 | 0.070 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2008 | 87 | 0.070 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2007 | 20 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 113 | 0.070 |
Why?
|
| Oxytocin | 1 | 2008 | 74 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 1169 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 824 | 0.060 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 56 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2011 | 632 | 0.060 |
Why?
|
| Version, Fetal | 1 | 2006 | 6 | 0.060 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 165 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2008 | 306 | 0.060 |
Why?
|
| Trachea | 1 | 2007 | 209 | 0.060 |
Why?
|
| Potassium Chloride | 1 | 2005 | 55 | 0.060 |
Why?
|
| Postpartum Period | 1 | 2007 | 231 | 0.060 |
Why?
|
| Twins, Monozygotic | 1 | 2005 | 128 | 0.060 |
Why?
|
| Cryptorchidism | 1 | 2005 | 37 | 0.060 |
Why?
|
| Injections | 1 | 2005 | 155 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 838 | 0.060 |
Why?
|
| Fetus | 1 | 2008 | 601 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 17415 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2011 | 12963 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 854 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 178 | 0.060 |
Why?
|
| Anemia | 1 | 2008 | 350 | 0.050 |
Why?
|
| Emergencies | 1 | 2005 | 187 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2008 | 811 | 0.050 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2012 | 6560 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 1583 | 0.050 |
Why?
|
| Hypospadias | 1 | 2005 | 80 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 1704 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 144 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 819 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 274 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1098 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 87 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 574 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2298 | 0.050 |
Why?
|
| Acute Disease | 1 | 2005 | 1187 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 493 | 0.050 |
Why?
|
| United States | 3 | 2017 | 11649 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2016 | 3121 | 0.050 |
Why?
|
| Kidney | 1 | 2008 | 1346 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 891 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2004 | 2864 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1314 | 0.040 |
Why?
|
| Heart | 1 | 2005 | 697 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 240 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 128 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 255 | 0.040 |
Why?
|
| Pregnancy Rate | 1 | 2000 | 40 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2004 | 1028 | 0.040 |
Why?
|
| Infant | 1 | 2016 | 13143 | 0.040 |
Why?
|
| Critical Care | 1 | 2005 | 695 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 2115 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1598 | 0.040 |
Why?
|
| Incidence | 1 | 2006 | 3369 | 0.040 |
Why?
|
| Meningitis | 1 | 2018 | 101 | 0.030 |
Why?
|
| Labor, Obstetric | 1 | 2018 | 97 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2018 | 95 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 1554 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2018 | 98 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 241 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 291 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5416 | 0.030 |
Why?
|
| Walking | 1 | 2018 | 233 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 191 | 0.030 |
Why?
|
| Male | 3 | 2025 | 65305 | 0.030 |
Why?
|
| Trophoblasts | 1 | 2016 | 122 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 9966 | 0.030 |
Why?
|
| Neural Tube Defects | 1 | 2018 | 359 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 398 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 566 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 3676 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 103 | 0.030 |
Why?
|
| Vagina | 1 | 2013 | 204 | 0.020 |
Why?
|
| Chorionic Villi Sampling | 1 | 2011 | 46 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 20560 | 0.020 |
Why?
|
| Animals | 2 | 2003 | 35889 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 2011 | 123 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2013 | 393 | 0.020 |
Why?
|
| Physician's Role | 1 | 2011 | 171 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2011 | 246 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 349 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 481 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1461 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1225 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 901 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2011 | 1100 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1652 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 97 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2004 | 240 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 917 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1237 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 29017 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 2632 | 0.010 |
Why?
|